Does TRT Cause Man Boobs? Gynaecomastia Explained

Does TRT cause man boobs? Testosterone replacement therapy (TRT) can lead to gynaecomastia, the medical term for enlarged glandular breast tissue in men, though not everyone who uses it is affected. This occurs because testosterone can be converted into oestradiol through a process called aromatisation, and when oestrogen levels rise relative to testosterone, breast tissue may respond by growing. Understanding who is most at risk, how to prevent it, and when to seek medical advice is essential for anyone on or considering TRT.

Can testosterone replacement therapy cause man boobs?

TRT can cause gynaecomastia by raising oestradiol levels through aromatisation of testosterone, leading to glandular breast tissue growth beneath one or both nipples.

Testosterone replacement therapy (TRT) can cause gynaecomastia, the medical term for the development of enlarged breast tissue in men, though it does not affect every person who uses it. Gynaecomastia is distinct from pseudogynaecomastia, which refers to fat accumulation in the chest area without true glandular tissue growth. TRT-related gynaecomastia involves actual proliferation of glandular breast tissue, typically presenting as a firm or rubbery lump beneath one or both nipples, sometimes accompanied by tenderness or sensitivity.^[1][2]

The condition arises because testosterone, once introduced into the body, can be converted into oestradiol (a form of oestrogen) through a natural process called aromatisation. When oestrogen levels rise relative to testosterone, breast tissue can respond by growing. This hormonal imbalance is the central mechanism behind TRT-associated gynaecomastia.

Some degree of breast tissue sensitivity or mild swelling is relatively common in the early weeks of TRT, particularly as hormone levels are being established. In many cases this settles once levels stabilise. However, persistent or progressive breast tissue growth warrants clinical review. Overall TRT monitoring follows UK clinical guidance, such as that published by the British Society for Sexual Medicine (BSSM), but breast changes should prompt an earlier review rather than waiting for a scheduled appointment. If you are considering TRT or are already on it and have concerns about breast changes, speaking with a qualified prescriber is the appropriate first step.

Why Does TRT Sometimes Lead to Gynaecomastia?

TRT raises oestradiol via aromatisation; higher doses, injectable formulations with pronounced peaks, and lower SHBG levels all increase the risk of oestrogen-driven breast tissue growth.

TRT leads to gynaecomastia primarily because exogenous testosterone is converted to oestradiol via the enzyme aromatase, which is found in adipose (fat) tissue, the liver, and other organs.^[11][12] When testosterone levels rise, more substrate is available for aromatisation, producing more oestradiol. If oestradiol levels become elevated relative to testosterone, breast glandular tissue, which contains oestrogen receptors, can begin to proliferate.

The type of TRT preparation used can influence this risk. UK-licensed injectable formulations include testosterone undecanoate (Nebido) and mixed-ester testosterone (Sustanon 250).^[1][2] Longer-acting or higher-dose injectable preparations can produce more pronounced peaks in testosterone levels, which may drive greater aromatisation and higher oestradiol levels. UK-licensed transdermal preparations, such as testosterone gel (for example Testogel or Tostran), tend to produce more stable serum levels and may be associated with a lower risk of oestradiol spikes, though individual responses vary and this has not been definitively established in comparative trials.^[3]

Dose is another important factor. Higher doses of testosterone provide more substrate for aromatisation and a higher likelihood of oestradiol-related side effects, including gynaecomastia. Sex hormone-binding globulin (SHBG) also plays a role: men with lower SHBG levels have more free testosterone available for conversion to oestradiol, which may increase their risk of gynaecomastia.^[9][10]

It is important to recognise that oestrogen is not inherently harmful in men. It plays a role in bone density, cardiovascular health, and libido. The aim of TRT management is not to eliminate oestrogen but to maintain a balanced hormonal environment. In UK practice, routine monitoring focuses on serum testosterone levels and clinical response. Oestradiol is measured when clinically indicated, for example when symptoms such as gynaecomastia or other oestrogen-related effects arise, rather than as a routine test for all men on TRT. This approach is consistent with BSSM guidance.

Who is most at risk of developing breast tissue growth on TRT?

Men with higher body fat, older age, lower SHBG, genetic predisposition to high aromatase activity, or concurrent use of certain medicines face the greatest risk of TRT-related gynaecomastia.

Certain individuals are more likely to develop gynaecomastia during TRT, and understanding these risk factors can help clinicians tailor monitoring and management accordingly. Men with higher levels of body fat are at greater risk because adipose tissue is the primary site of aromatase activity. Greater fat mass means more conversion of testosterone to oestradiol, raising the likelihood of oestrogen-driven breast tissue growth.

Age is also a relevant factor. Older men tend to have higher baseline aromatase activity, which can increase oestradiol production relative to testosterone. SHBG levels generally rise with age in men, which reduces the proportion of free testosterone; however, the net effect on oestradiol exposure depends on the individual hormonal picture and the TRT regimen used.

Genetic predisposition may also play a role. Some individuals appear to have naturally higher aromatase activity, making them more prone to oestrogen-related side effects. A personal or family history of gynaecomastia may indicate this tendency, though the evidence base for this is largely observational.

Other contributing factors include:

• Concurrent use of certain medicines, including spironolactone, finasteride, dutasteride, some antipsychotics, some antiretrovirals, cimetidine, and anabolic steroids, which can independently affect hormone balance. The NICE CKS guideline on gynaecomastia and the BNF provide a more comprehensive list of medicines associated with this condition.

• Liver disease, which impairs oestrogen metabolism and can allow oestradiol to accumulate

• Hypogonadism with pre-existing hormonal imbalance, where the baseline oestrogen-to-testosterone ratio is already skewed before TRT begins

• Supraphysiological dosing, particularly in men using TRT outside a supervised clinical setting

In UK practice, monitoring on TRT routinely includes serum testosterone and clinical assessment. Oestradiol and SHBG are measured when clinically indicated, such as when gynaecomastia or other oestrogen-related symptoms develop, allowing dose adjustments or additional interventions before significant breast tissue changes progress.

What can be done to prevent or treat gynaecomastia during TRT?

Dose reduction or preparation change is the first step; off-label aromatase inhibitors or SERMs may be used under specialist supervision, and surgery is reserved for persistent cases.

Several clinical strategies can help prevent or manage gynaecomastia in men receiving TRT, and the appropriate approach depends on the severity of symptoms, the underlying hormonal picture, and individual patient factors. The first step is always a thorough review of current TRT dosing and blood results, as dose reduction or a change in preparation may be sufficient to bring oestradiol levels back into an acceptable range.

Aromatase inhibitors (AIs), such as anastrozole, are sometimes used alongside TRT to reduce the conversion of testosterone to oestradiol. It is important to note that this is an off-label use in the UK: anastrozole does not hold a UK marketing authorisation for gynaecomastia, and its use for this purpose is typically initiated and supervised in secondary care (for example by an endocrinologist or urologist).^[4][8] These are prescription-only medicines and should only be used under medical supervision, as excessive suppression of oestradiol can have adverse effects on bone density, lipid profiles, and mood.^[4][13] Medical therapy tends to be more effective when started early, before glandular tissue becomes fibrotic.

Selective oestrogen receptor modulators (SERMs), such as tamoxifen, can be used to block oestrogen's action at breast tissue receptors. Tamoxifen is also used off-label in the UK for this indication and, like AIs, is generally initiated under specialist oversight. It may help reduce tenderness and tissue growth, particularly in recent-onset gynaecomastia. The BNF and NICE CKS guideline on gynaecomastia provide further detail on these off-label options.

For persistent or significant gynaecomastia that does not respond to hormonal management, surgical referral may be considered. This typically follows assessment by a GP and onward referral to breast, endocrine, or plastic surgery services. Procedures such as subcutaneous mastectomy or liposuction can remove glandular tissue, though surgery carries its own risks and is generally reserved for cases where conservative measures have failed.

Lifestyle measures, including weight management to reduce adipose tissue and therefore aromatase activity, can also support hormonal balance. Men on TRT should attend all scheduled monitoring appointments and report any breast changes promptly to their prescribing clinician.

When Should You Speak to a Doctor About Breast Changes on TRT?

Speak to your GP or prescriber promptly if you notice a new breast lump, persistent tenderness, nipple discharge, or visible swelling, as these require clinical assessment to exclude serious causes.

You should speak to your GP or prescribing clinician promptly if you notice any new or changing breast symptoms while on TRT, as early assessment allows for timely adjustment of treatment and reduces the likelihood of significant tissue changes becoming established. Symptoms that warrant a clinical review include:

• A firm or rubbery lump beneath one or both nipples

• Breast tenderness or sensitivity that persists beyond the first few weeks of TRT

• Visible swelling or enlargement of breast tissue

• Nipple discharge of any kind

• Asymmetrical breast changes, where one side is noticeably more affected than the other

While gynaecomastia caused by TRT is generally benign, it is important not to assume that all breast changes in men are hormone-related. Male breast cancer, though uncommon, does occur. NICE guidance (NG12: Suspected cancer: recognition and referral) supports urgent referral via the two-week-wait pathway for men aged 50 or over who present with a unilateral, firm subareolar mass with or without nipple changes or skin changes. Features that should prompt urgent assessment regardless of age include bloodstained nipple discharge, skin tethering or dimpling, and palpable axillary lymph nodes.^[18] Any new breast lump in a man should be assessed by a clinician to exclude other causes.

Nipple discharge, particularly if bloodstained or from a single duct, should be assessed without delay. Contact your GP in the first instance; if you are unable to reach your GP and require urgent advice, NHS 111 can help direct you to the appropriate service.

Suspected side effects from TRT can be reported to the MHRA via the Yellow Card scheme at yellowcard.^[7]mhra.gov.uk, which helps regulators monitor the safety of medicines in clinical use. Regular follow-up with your prescribing clinician, including scheduled blood tests to monitor hormone levels, is the most effective way to detect and manage breast changes before they become a significant concern.

Scientific References

1. Nebido 1000 mg/4 ml solution for injection – Summary of Product Characteristics.
2. Sustanon 250, 250 mg/ml solution for injection – Summary of Product Characteristics.
3. Testosterone.
4. Anastrozole.
5. Tamoxifen.
6. Adverse reactions to drugs.
7. The Yellow Card scheme: guidance for healthcare professionals, patients and the public.
8. MHRA authorises anastrozole to prevent breast cancer.
9. Drug-induced gynaecomastia: an evidence-based review.
10. Drug-induced gynecomastia.
11. The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters.
12. Tissue-specific promoters regulate aromatase cytochrome P450 expression.
13. Estrogens and bone health in men.
14. Adverse effects of androgen deprivation therapy and strategies to mitigate them.
15. Tamoxifen in men: a review of adverse events.
16. Incidence, management, and prevention of gynaecomastia and breast pain in patients with prostate cancer undergoing antiandrogen therapy: a systematic review and meta-analysis.
17. The 'male menopause'.
18. Symptoms of breast cancer in women.

Frequently Asked Questions